JPRN-UMIN000010068已完成2 期
Phase II Clinical trial of personalized peptide vaccine for patients with various types of cancers - Effect of sequencial change of vaccine antigens - - Personalized peptide vaccine trial for cancer patients -Effect of sequencial change of vaccine antigens
Kurume University Cancer Vaccine Center0 个研究点目标入组 100 人开始时间: 2013年3月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The following patients must be excluded: 1) Patients with severe symptoms (active and severe infectious disease, circulatory disease, respiratory disease, kidney disease, immunodeficiency, disturbance of coagulation). 2) Patients with the past history of severe allergic reactions. 3) Pregnant, nursing, or who wants pregnancy. Patients with no acceptance of use of effective contraception during and for at least 70 days after study participation. 4) Patients with the past history of cancer peptide vaccinations. 5) Patients with the past history of cancer peptide vaccinations.
研究者
相似试验
已完成
2 期
Phase II Clinical trial of personalized peptide vaccine for cancer patients - Effect of extended dose interval on the immun inductionmalignant tumorJPRN-UMIN000006927Kurume University Cancer Vaccine Center60
已完成
2 期
Phase II Clinical trial of personalized peptide vaccine for cancer patientsmalignant tumorJPRN-UMIN000001482Kurume University Cancer Vaccine Center150
已完成
2 期
Phase II Clinical trial of personalized peptide vaccine for patients with maligant tumors (gastrointestinal cancers, hepato-biliary-pancreatic cancers, thoracic malignant tumors, non-epithelial malignant tumors, genitourinary cancers, gynecological cancers, breast cancers, and rare cancers) - Effect of extended interval dosing on immune responsesmalignant tumorJPRN-UMIN000011230Kurume University CanCER Vaccine Center800
已完成
2 期
Phase II clinical trial of personalized peptide vaccination for standard therapy failed or unoperable Pancreatic cancer patientsPancreatic cancerJPRN-UMIN000001881Kurume University Cancer Vaccine Center100
已完成
2 期
Phase II clinical trial of personalized peptide vaccination for Pancreatic cancer patientsPancreatic cancerJPRN-UMIN000002908Kurume University Center Vaccine Center100